Notably, most of the previous anti-HIV infection studies use the recombinant C-terminal peptide of IL16 instead of full-length IL16 [16–20], it is reasonable since the C-terminal peptide is secreted to self-aggregate and becomes a bioactive form of IL6 that can bind to CD4. This evidence concerns the gene IL16 and HIV infectious disease.